Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Centergrid.413967.e, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0012622. doi: 10.1128/aac.00126-22. Epub 2022 Jun 28.
Although several clinical variables have been reported as risk factors for recurrence of Staphylococcus aureus infection, most studies have not considered competing risk events that may overestimate the risk. In this study, we performed competing risk analysis to identify risk factors related to 90-day recurrence in patients with S. aureus bacteremia (SAB) using a large cohort data from a single tertiary hospital in South Korea. All adults who experienced SAB during admission were prospectively enrolled from August 2008 to December 2019. After the day of the first positive blood culture, recurrence and all-cause mortality were assessed for 90 days. Recurrence was defined as a development of symptoms or signs of infection with or without repeated bacteremia after >7 days of negative blood culture and clinically apparent improvement. Subdistribution hazard ratios (sHR) for recurrence and all-cause mortality were estimated using Fine and Gray models. Of 1,725 SAB patients, including 885 cases (51.3%) of methicillin-resistant S. aureus (MRSA) bacteremia, 85 (5.0%) experienced recurrence during the study period. In a multivariate Fine and Gray regression model, the presence of a vascular graft (subdistribution HR [sHR], 3.48; 95% confidence interval [CI], 1.90-6.40), nasal MRSA carriage (sHR, 2.10; 95% CI, 1.28-3.44), methicillin resistance (sHR, 1.69; 95% CI, 1.00-2.84), and rifampicin resistance (sHR, 2.20; 95% CI, 1.12-4.33) were significantly associated with 90-day recurrence. In a large cohort of SAB patients with a high prevalence of MRSA, indwelling vascular graft, nasal MRSA carriage, methicillin resistance, and rifampicin resistance were potential risk factors for recurrence of S. aureus infection.
尽管已经报道了几种临床变量是金黄色葡萄球菌感染复发的危险因素,但大多数研究并未考虑可能高估风险的竞争风险事件。在这项研究中,我们使用来自韩国一家三级医院的大型队列数据进行竞争风险分析,以确定金黄色葡萄球菌菌血症 (SAB) 患者 90 天复发的相关危险因素。所有在住院期间经历 SAB 的成年人均从 2008 年 8 月至 2019 年 12 月前瞻性入组。在第一次阳性血培养后的第 1 天起,评估 90 天内的复发和全因死亡率。复发定义为在连续 7 天以上的阴性血培养后出现感染症状或体征且临床明显改善,或出现反复菌血症。使用 Fine 和 Gray 模型估计复发和全因死亡率的亚分布风险比 (sHR)。在 1725 例 SAB 患者中,包括 885 例(51.3%)耐甲氧西林金黄色葡萄球菌(MRSA)菌血症,85 例(5.0%)在研究期间发生复发。在多变量 Fine 和 Gray 回归模型中,血管移植物的存在(亚分布 HR [sHR],3.48;95%置信区间 [CI],1.90-6.40)、鼻腔 MRSA 携带(sHR,2.10;95%CI,1.28-3.44)、耐甲氧西林(sHR,1.69;95%CI,1.00-2.84)和利福平耐药(sHR,2.20;95%CI,1.12-4.33)与 90 天复发显著相关。在一个具有高 MRSA 患病率的 SAB 患者大队列中,留置血管移植物、鼻腔 MRSA 携带、耐甲氧西林和利福平耐药是金黄色葡萄球菌感染复发的潜在危险因素。